| Entry |
|
|---|
| Name |
Topotecan hydrochloride (USAN);
Nogitecan hydrochloride (JAN);
Hycamtin (TN);
Potactasol (TN) |
|---|
| Product |
|
|---|
| Generic |
|
|---|
| Formula |
C23H23N3O5. HCl
|
|---|
| Exact mass |
457.1404
|
|---|
| Mol weight |
457.90
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
|
|---|
| Remark |
| Therapeutic category: | 4240 |
| Product (DG00725): | D02168<JP/US> |
|
|---|
| Efficacy |
Antineoplastic, Topoisomerase I inhibitor |
|---|
| Disease |
|
|---|
| Comment |
Camptothecin [CPD: C01897] derivative
|
|---|
| Target |
|
|---|
| Metabolism |
Transporter: ABCB1 [HSA: 5243], ABCG2 [HSA: 9429], ABCC4 [HSA: 10257]
|
|---|
| Interaction |
|
|---|
| Structure map |
| map07042 | Antineoplastics - agents from natural products |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01C PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS
L01CE Topoisomerase 1 (TOP1) inhibitors
L01CE01 Topotecan
D02168 Topotecan hydrochloride (USAN) <JP/US>
USP drug classification [BR:br08302]
Antineoplastics
Molecular Target Inhibitors
Topoisomerase Inhibitors
Topotecan
D02168 Topotecan hydrochloride (USAN)
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
424 Plant extract preparations
4240 Plant extract preparations
D02168 Topotecan hydrochloride (USAN); Nogitecan hydrochloride (JAN)
Drug groups [BR:br08330]
Antineoplastic
DG01529 Topoisomerase inhibitor
DG01526 Topoisomerase I inhibitor
DG00725 Topotecan
D02168 Topotecan hydrochloride
Transporter substrate
DG01665 ABCB1 substrate
DG00725 Topotecan
D02168 Topotecan hydrochloride
DG02920 ABCC4 substrate
DG00725 Topotecan
D02168 Topotecan hydrochloride
DG01913 ABCG2 substrate
DG00725 Topotecan
D02168 Topotecan hydrochloride
Target-based classification of drugs [BR:br08310]
Enzymes
Isomerases (EC5)
DNA topoisomerase
TOP1
D02168 Topotecan hydrochloride (USAN) <JP/US>
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D02168
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D02168
Drug metabolizing enzymes and transporters [br08309.html]
Drug transporters
D02168
Drug groups [BR:br08330]
Antineoplastic
DG01529 Topoisomerase inhibitor
DG01526 Topoisomerase I inhibitor
DG00725 Topotecan
Transporter substrate
DG01665 ABCB1 substrate
DG00725 Topotecan
DG02920 ABCC4 substrate
DG00725 Topotecan
DG01913 ABCG2 substrate
DG00725 Topotecan
|
|---|
| Other DBs |
|
|---|
| KCF data |
ATOM 32
1 C8y C 32.0215 -19.7287
2 C8y C 29.7683 -20.8552
3 N4y N 30.6133 -19.7285
4 C1x C 29.7683 -18.6020
5 C8y C 28.4540 -20.4326
6 C8y C 28.4540 -19.0244
7 C8x C 27.2336 -18.3673
8 N5x N 27.2336 -21.1367
9 C8y C 26.0131 -20.4796
10 C8y C 26.0131 -19.0714
11 C8y C 24.8396 -18.3673
12 C8y C 23.6191 -19.0714
13 C8x C 23.6191 -20.4796
14 C8x C 24.8396 -21.1838
15 C1b C 24.8396 -17.0060
16 N1c N 23.6191 -16.3019
17 C1a C 23.6191 -14.8937
18 C1a C 22.4456 -17.0060
19 O1a O 22.3987 -18.4143
20 O5x O 32.7141 -18.5298
21 C8y C 32.7340 -20.9631
22 C1x C 34.1280 -20.9630
23 C8y C 32.0340 -22.1755
24 C8x C 30.6115 -22.1758
25 O7x O 34.8251 -22.1700
26 C7x C 34.1346 -23.3658
27 C1z C 32.7215 -23.3659
28 O6a O 34.8251 -24.5616
29 C1b C 31.3147 -23.3660
30 C1a C 30.6287 -24.5679
31 O1a O 32.7215 -24.7659
32 X Cl 36.6837 -19.7288
BOND 35
1 2 3 1
2 3 4 1
3 4 6 1
4 5 2 1
5 5 6 2
6 6 7 1
7 7 10 2
8 9 8 2
9 8 5 1
10 9 10 1
11 10 11 1
12 11 12 2
13 12 13 1
14 13 14 2
15 14 9 1
16 11 15 1
17 15 16 1
18 16 17 1
19 16 18 1
20 3 1 1
21 12 19 1
22 1 20 2
23 1 21 1
24 21 22 1
25 21 23 2
26 23 24 1
27 24 2 2
28 22 25 1
29 25 26 1
30 26 27 1
31 27 23 1
32 26 28 2
33 27 29 1 #Down
34 29 30 1
35 27 31 1 #Up
|
|---|